Skip to content
NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP

Gossamer Bio, Inc. GOSS

9 fiscal years on record · USD · FY2025 reported · SEC filings only
$48.5M
▼ 57.7% YoY
$-170.4M
$-171.3M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Growth

USD 48.5M
Revenue, FY2025 · full 9-year series below
Revenue $M Net income $M
FY2025 · Revenue 48.5 · Net income -170.4
50M100M-100M-200M
2017202020232025
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

−351 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -352.2% · Net -351.5%
-100%-200%-300%
201720212025
ROE
FY2024 · ROE -122.5%
-200%-400%
201720212025
Three returns, three denominators.
Return on equityNot applicable: equity was zero or negative in this period, so return on equity has no meaning.

Return on equity has no reading this year — return on capital employed, just below, still does: -90%.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -171.3
-100M-200M
201720212025

Total assetsUSD 172.2M
EquityUSD -122.8M
CashUSD 37.7M
Current ratio2.64×

Equity funds -71% of total assets.

The 9-year record

9 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
GOSS, 9-year financial record
Metric 202520242023202220212020201920182017
Revenue $B0.00.10.00.0◌◌◌◌◌
Operating income $B−0.2−0.1−0.2−0.2−0.2−0.2−0.2−0.1−0.0
EBITDA $B−0.2−0.1−0.2−0.2−0.2−0.2−0.2−0.1−0.0
Income tax $B−0.00.00.00.0◌◌0.00.00.0
Net income $B−0.2−0.1−0.2−0.2−0.2−0.2−0.2−0.1−0.0
Free cash flow $B−0.2−0.0−0.2−0.2−0.2−0.2−0.1−0.1◌
EPS, diluted $−0.75−0.25−1.18−2.71−3.13−3.55−3.29−22.59−0.74
Dividend / sh $◌◌◌◌◌◌◌◌◌
Payout % — not applicable: no dividend—————————
ROE %—−122.5−480.5−343.5−105.8−72.3———
Shares out B0.230.230.230.090.080.070.060.01◌

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 34 reconciliationsAUDITED

Reconciled in 9 of the 9 fiscal years we could check. 22 checks were skipped: the balance sheet is not tagged before 2018. 10 checks were skipped: EPS is not tagged before 2017.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2017

Share this section

Download image